News Releases

Date Title and Summary View
Feb 08, 2018
Feb 08, 2018
Feb 07, 2018
Johnson & Johnson to Participate in RBC Capital Markets 2018 Global Healthcare Conference
NEW BRUNSWICK, N.J. , Feb. 7, 2018 /PRNewswire/ --  Johnson & Johnson ( NYSE : JNJ) will participate in the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, Feb. 21 , at the Lotte New York Palace in New York City.  Dominic Caruso , Executive Vice President, Chief Financial
Jan 31, 2018
Johnson & Johnson to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J. , Jan. 31, 2018 /PRNewswire/ --  Johnson & Johnson ( NYSE : JNJ) will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, Feb. 14 , at Lotte New York Palace , NY.  Dominic Caruso , Executive Vice President, Chief Financial Officer will
Jan 25, 2018
Jan 23, 2018
Johnson & Johnson Reports 2017 Fourth-Quarter Results:
2017 Fourth-Quarter Sales of $20.2 Billion Increased 11.5%; EPS was a Loss of $3.99
2017 Full-Year Sales of $76.5 Billion Increased 6.3%, Full-Year EPS was $0.47
Adjusted 2017 Fourth-Quarter EPS was $1.74, an Increase of 10.1%*, and Adjusted 2017 Full-Year EPS was $7.30, an Increase of 8.5%*
Continued Sales Acceleration in Fourth Quarter
Strong 2017 Full-Year Adjusted EPS Growth of Approximately 8.5%*
Company Records Special Item Charge of Approximately $13.6 Billion Related to Recently Enacted Tax Legislation
Jan 02, 2018
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2018
NEW BRUNSWICK, N.J. , Jan. 2, 2018 /PRNewswire/ --  Johnson & Johnson ( NYSE : JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2018 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders of
Dec 21, 2017
Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy
CAR-T BCMA in Development for Patients with Multiple Myeloma
Dec 21, 2017
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
Apalutamide is the First Agent Submitted for Approval to Treat Earlier Stage Castration-Resistant Prostate Cancer at High Risk for Metastasis
Dec 19, 2017
Johnson & Johnson to Participate in 36th Annual JP Morgan Health Care Conference
NEW BRUNSWICK, N.J. , Dec. 19, 2017 /PRNewswire/ -- Johnson & Johnson ( NYSE : JNJ) will participate in the 36 th Annual JP Morgan Health Care Conference on Monday, Jan. 8 , at the Westin St. Francis in San Francisco.  Alex Gorsky , Chairman and Chief Executive Officer, will represent the Company
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.